Becoming AstraZeneca
Since 1912, AstraZeneca has been committed to patient health by continually
working to discover, develop, and deliver innovative healthcare solutions
that help enrich the lives of patients, families, and communities.
In order to recount the rich history of AstraZeneca, it is necessary to
also tell the story of each of the companies on which our current mission
was built, along with the history of resulting mergers, acquisitions, and
milestones.
AstraZeneca milestones 1981-2000
|
|
1981
|
TENORMIN® (atenolol) is introduced,
a beta blocker for the treatment of hypertension.
|
|
1982
|
Just one year after being launched,
TENORMIN becomes the #1 selling beta blocker in the US
Launch of
PULMICORT® (budesonide), an anti-inflammatory corticosteroid for the treatment of asthma.
|
|
1983
|
Launch of
RHINOCORT®
(budesonide), made from the same active substance as PULMICORT,
for the relief of symptoms caused by allergic rhinitis.
|
|
1984
|
Launch of
TONOCARD® (tocainide HCI), the anti arrhythmic agent.
Launch of
EMLA® (lidocaine 2.5% and prilocaine 2.5%) Cream, a topical
anesthetic used primarily to diminish or prevent pain in needle procedures.
|
|
1989
|
Launch of
PRILOSEC®
(omeprazole), the proton pump inhibitor.
Introduction of DIPRIVAN® (propofol), the first I.V.-injectable emulsion, non-inhalant anesthetic for induction and maintenance.
|
|
1992
|
Launch of TOPROL XL® (metoprolol succinate) in the United States for the treatment of hypertension and angina.
|
|
1993
|
Launch of topical anesthetic EMLA Cream.
|
|
1994
|
Launch of RHINOCORT Nasal Inhaler.
|
|
1995
|
Launch of CASODEX® (bicalutamide), an antiandrogen for prostate cancer.
|
|
1998
|
Launch of ATACAND® (candesartan cilexetil), an angiotensin II receptor blocker for the treatment of hypertension.
CASODEX, becomes the most prescribed antiandrogen in the world.
ZOLADEX® (goserelin acetate implant) becomes the only LHRH agonist with FDA approval for early-stage prostate cancer.
ZESTRIL® (lisinopril) becomes the most prescribed ACE inhibitor in the US.
NOLVADEX® (tamoxifen citrate) is indicated to reduce the risk of breast cancer in women at high risk.
|
|
2000
|
ATACAND HCT® (candesartan cilexetil-hydrochlorothiazide) a second-line treatment for hypertension, receives FDA approval.
PULMICORT RESPULES® (budesonide inhalation suspension), for the control of persistent asthma in children as young as 12 months, receives FDA approval.
The FDA approves a new indication for ARIMIDEX® (anastrozole) for first-line treatment of advanced breast cancer in postmenopausal women.
|
|
